We also show that targeting IL-12/IL-23 production using Apilimod results in significant anti-proliferative responses in NSCLC cell lines, further underlining the therapeutic potential of targeting this pathway in cancer. This evidence concerns the gene IL23A and non-small cell lung carcinoma.